ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 16

Comprehensive Antibody Profiling Using High Density Peptide Arrays Reveals Novel Citrullinated Protein Targets in Rheumatoid Arthritis Serum Samples

Ken Lo1, Hanying Li2, Eric Sullivan2 and Jigar Patel2, 1Technology Innovation, Roche Sequencing Solutions - Madison, Madison, WI, 2Roche Sequencing Solutions - Madison, Madison, WI

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: autoantibodies, autoantigens, citrullination and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: B Cell Biology and Targets in Autoimmune and Inflammatory Disease Poster

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

Autoantibodies against citrullinated proteins are found in 64-89% of rheumatoid arthritis (RA) patients, with a specificity of 88-99%. While citrullinated vimentin, fibrin and histone have been implicated as targets of autoantibody reactivity, new targets, such as as Tenascin-C, continue to be uncovered. To this end, we performed an unbiased epitope-level characterization of autoantibodies from RA serum samples using a high density peptide microarray.

Methods:

Our high-density peptide array, comprised of over 4.6M peptides, contains the entire annotated human proteome from the UNIPROT database. The 20,188 unique proteins were represented as overlapping 16-mer peptides. In addition to native peptide sequences, sequences containing arginine residues were replaced with citrulline and lysine residues were replaced with homo-citrulline to provide a comprehensive screen against all possible epitopes. We analyzed IgG antibodies for 27 serum samples (9 control, 9 RA DMARDS responders and 9 RA DMARDS non-responders).

Results:

Autoantibody reactivity was seen ubiquitously in all RA serum samples, with citrullinated peptides being the most prevalent over homocitrullinated and native peptide sequences. Hierarchal clustering revealed strong autoantibody reactivity against citrullinated peptides in almost all (8/9) RA DMARDS non-responder and 4/9 RA DMARDS responder samples. Within this group of RA samples with high reactivity, identical immunodominant epitopes were observed in 959 proteins. Within the 959 proteins, which included previously known targets such as vimentin, fibrin and type II collagen, over half have not been previously associated with RA. These include proteins such as PATE4 and NENF.

Conclusion:

Using high-density peptide arrays, antibody reactivity was observed against citrullinated proteins that have not been previously associated with RA. These protein targets may further contribute to our understanding of the role of autoantibodies in RA pathophysiology.


Disclosure: K. Lo, Roche, 3,Roche, 1; H. Li, Roche, 3; E. Sullivan, Roche, 3; J. Patel, Roche, 3,Roche, 1.

To cite this abstract in AMA style:

Lo K, Li H, Sullivan E, Patel J. Comprehensive Antibody Profiling Using High Density Peptide Arrays Reveals Novel Citrullinated Protein Targets in Rheumatoid Arthritis Serum Samples [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/comprehensive-antibody-profiling-using-high-density-peptide-arrays-reveals-novel-citrullinated-protein-targets-in-rheumatoid-arthritis-serum-samples/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/comprehensive-antibody-profiling-using-high-density-peptide-arrays-reveals-novel-citrullinated-protein-targets-in-rheumatoid-arthritis-serum-samples/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology